Allspring Global Investments Holdings LLC boosted its position in shares of Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 30.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 454,154 shares of the company's stock after acquiring an additional 106,539 shares during the quarter. Allspring Global Investments Holdings LLC owned 1.73% of Abrdn Life Sciences Investors worth $6,113,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in the company. Comerica Bank bought a new position in shares of Abrdn Life Sciences Investors in the third quarter valued at about $42,000. Blue Bell Private Wealth Management LLC increased its stake in shares of Abrdn Life Sciences Investors by 60.4% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 10,125 shares of the company's stock worth $136,000 after purchasing an additional 3,811 shares during the period. International Assets Investment Management LLC lifted its holdings in Abrdn Life Sciences Investors by 3,424.5% during the 4th quarter. International Assets Investment Management LLC now owns 11,067 shares of the company's stock worth $149,000 after purchasing an additional 10,753 shares during the last quarter. Money Concepts Capital Corp bought a new stake in Abrdn Life Sciences Investors in the 4th quarter valued at $160,000. Finally, B. Riley Wealth Advisors Inc. acquired a new position in Abrdn Life Sciences Investors in the 4th quarter valued at $167,000. Institutional investors and hedge funds own 32.21% of the company's stock.
Abrdn Life Sciences Investors Price Performance
Abrdn Life Sciences Investors stock traded up $0.01 during midday trading on Friday, hitting $12.80. The company's stock had a trading volume of 94,301 shares, compared to its average volume of 112,022. The company has a 50-day moving average price of $13.57 and a two-hundred day moving average price of $13.08. Abrdn Life Sciences Investors has a 1-year low of $11.34 and a 1-year high of $14.37.
Abrdn Life Sciences Investors Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Thursday, February 22nd were given a $0.39 dividend. The ex-dividend date was Wednesday, February 21st. This represents a $1.56 dividend on an annualized basis and a dividend yield of 12.19%. This is a boost from Abrdn Life Sciences Investors's previous quarterly dividend of $0.30.
Abrdn Life Sciences Investors Company Profile
(
Free Report)
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
Read More
Before you consider Abrdn Life Sciences Investors, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abrdn Life Sciences Investors wasn't on the list.
While Abrdn Life Sciences Investors currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.
Get This Free Report
